To investigate NOP58 sumoylation in glioma cells, we immunoprecipitated endogenous NOP58 then performed immunoblotting with small ubiquitin-related modifier 2 (SUMO2) antibody, revealing that endogenous NOP58 was sumoylated by SUMO2 (Fig. 6f). This evidence concerns the gene SUMO2 and central nervous system cancer.